ORM-3819 promotes cardiac contractility through Ca(2+) sensitization in combination with selective PDE III inhibition, a novel approach to inotropy.

导出 LinkOut

翻译打印收藏纠错

第一作者： László,Nagy

第一单位： Division of Clinical Physiology, Institute of Cardiology, Research Centre for Molecular Medicine, Faculty of Medicine, University of Debrecen, Hungary Móricz Zs. krt. 22 Hungary, 4032 Debrecen, Hungary.

作者： László,Nagy ^[1] ; Piero,Pollesello ^[2] ; Heimo,Haikala ^[2] ; Ágnes,Végh ^[3] ; Tia,Sorsa ^[2] ; Jouko,Levijoki ^[2] ; Szabolcs,Szilágyi ^[1] ; István,Édes ^[1] ; Attila,Tóth ^[1] ; Zoltán,Papp ^[4] ; Julius Gy,Papp ^[5]

作者单位： Division of Clinical Physiology, Institute of Cardiology, Research Centre for Molecular Medicine, Faculty of Medicine, University of Debrecen, Hungary Móricz Zs. krt. 22 Hungary, 4032 Debrecen, Hungary. ^[1] Orion Pharma, Drug Discovery and Pharmacology, Espoo, Finland. ^[2] Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary. ^[3] Division of Clinical Physiology, Institute of Cardiology, Research Centre for Molecular Medicine, Faculty of Medicine, University of Debrecen, Hungary Móricz Zs. krt. 22 Hungary, 4032 Debrecen, Hungary. Electronic address: pappz@med.unideb.hu. ^[4] MTA-SZTE Research Group of Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged, Hungary. ^[5]

关键词 Ca(2+) sensitization Levosimendan Myocardial stunning ORM-3819 Phosphodiesterase III inhibition Positive inotropic agent